{"publication_id":"4e5f3bb0-f06e-45a7-a244-efc65bf18284","content_hash":"sha256:9aff9e7a07ae05a3f8fcaa9ebdeaa2ceae49eea3656abe2876713e8836144de7","nodes":[{"id":"4e5f3bb0-f06e-45a7-a244-efc65bf18284","type":"publication","title":"mtor: receipt-backed evidence fronts"},{"id":"claim_1","type":"claim","text":"Across retrieved fact-level receipts for mtor, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?"},{"id":"claim_2","type":"claim","text":"Finding: observed no increase of 1-year PTDM versus CNI plus antiproliferative agents relative risk 1.16, 95% CI 0.97–1.38, P = .10"},{"id":"claim_3","type":"claim","text":"Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. [primary; 2013] doi:10.1016/j.celrep.2013.07.030"},{"id":"claim_4","type":"claim","text":"Finding: Metformin decreased tumor burden by 72%, which correlated with decreased cellular proliferation and marked inhibition of mTOR in tumors."},{"id":"claim_5","type":"claim","text":"This receipt-backed scoping note has one bounded signal: mtor shows context-dependent, not convergent, associations across this 5-source primary/review bundle (2010-2024). Grouped by direction, directionally favorable: RAD001 improved influenza vaccine response by ~20% in the elderly; Metformin decreased tumor burden by 72%, which correlated with decreased cellular proliferation and marked inhibition... | other/mixed: observed no increase of 1-year PTDM versus CNI plus antiproliferative agents relative risk 1.16, 95% CI 0.97–1.38, P =...; Patients treated with CNIs had a higher proportion of HCC within Milan criteria (74% vs. 69%). The source facts cover 5 population context(s) and 5 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. Concrete source-level examples: observed no increase of 1-year PTDM versus CNI plus antiproliferative agents relative risk 1.16, 95% CI 0.97–1.38, P = .10; RAD001 improved influenza vaccine response by ~20% in the elderly; Patients treated with CNIs had a higher proportion of HCC within Milan criteria (74% vs. 69%)."},{"id":"claim_6","type":"claim","text":"other/mixed: International consensus on post-transplantation diabetes mellitus — observed no increase of 1-year PTDM versus CNI plus antiproliferative agents relative risk 1.16, 95% CI 0.97–1.38, P = .10"},{"id":"claim_7","type":"claim","text":"other/mixed: Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. — exhibit an approximately 20% increase in median survival."},{"id":"claim_8","type":"claim","text":"directionally favorable: Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis — Metformin decreased tumor burden by 72%, which correlated with decreased cellular proliferation and marked inhibition of mTOR in tumors."},{"id":"claim_9","type":"claim","text":"Candidate moderators are population or indication, endpoint, comparator, and study design/evidence type; these dimensions explain why the receipts should be read as divergent evidence fronts, not one pooled effect."},{"id":"claim_10","type":"claim","text":"The selected receipts group because each carries a fact-level extraction for mtor; they separate by context (animal model, human clinical/observational, and other source context) and endpoint, so they are not interchangeable evidence for one pooled claim."},{"id":"claim_11","type":"claim","text":"Source-literature boundary for mtor: the listed sources define separate evidence fronts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources."},{"id":"claim_12","type":"claim","text":"The signal is purely descriptive of effect-direction heterogeneity; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate."},{"id":"source_1","type":"source","study":"International consensus on post-transplantation diabetes mellitus","year":2024,"doi":"10.1093/ndt/gfad258","url":"https://doi.org/10.1093/ndt/gfad258","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"mTOR inhibition improves immune function in the elderly","year":2014,"doi":"10.1126/scitranslmed.3009892","url":"https://doi.org/10.1126/scitranslmed.3009892","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.","year":2014,"doi":"10.1111/tri.12372","url":"https://doi.org/10.1111/tri.12372","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_4","type":"source","study":"Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression.","year":2013,"doi":"10.1016/j.celrep.2013.07.030","url":"https://doi.org/10.1016/j.celrep.2013.07.030","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis","year":2010,"doi":"10.1158/1940-6207.capr-10-0055","url":"https://doi.org/10.1158/1940-6207.capr-10-0055","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"}],"edges":[{"from":"4e5f3bb0-f06e-45a7-a244-efc65bf18284","to":"claim_1","type":"contains_claim"},{"from":"4e5f3bb0-f06e-45a7-a244-efc65bf18284","to":"claim_2","type":"contains_claim"},{"from":"4e5f3bb0-f06e-45a7-a244-efc65bf18284","to":"claim_3","type":"contains_claim"},{"from":"4e5f3bb0-f06e-45a7-a244-efc65bf18284","to":"claim_4","type":"contains_claim"},{"from":"4e5f3bb0-f06e-45a7-a244-efc65bf18284","to":"claim_5","type":"contains_claim"},{"from":"4e5f3bb0-f06e-45a7-a244-efc65bf18284","to":"claim_6","type":"contains_claim"},{"from":"4e5f3bb0-f06e-45a7-a244-efc65bf18284","to":"claim_7","type":"contains_claim"},{"from":"4e5f3bb0-f06e-45a7-a244-efc65bf18284","to":"claim_8","type":"contains_claim"},{"from":"4e5f3bb0-f06e-45a7-a244-efc65bf18284","to":"claim_9","type":"contains_claim"},{"from":"4e5f3bb0-f06e-45a7-a244-efc65bf18284","to":"claim_10","type":"contains_claim"},{"from":"4e5f3bb0-f06e-45a7-a244-efc65bf18284","to":"claim_11","type":"contains_claim"},{"from":"4e5f3bb0-f06e-45a7-a244-efc65bf18284","to":"claim_12","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}